诚意药业
(603811)
| 流通市值：44.42亿 | | | 总市值：44.42亿 |
| 流通股本：3.27亿 | | | 总股本：3.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 416,670,322.17 | 185,591,983.95 | 714,369,070.89 | 520,542,330.59 |
| 营业收入 | 416,670,322.17 | 185,591,983.95 | 714,369,070.89 | 520,542,330.59 |
| 二、营业总成本 | 302,365,752.25 | 140,420,568.18 | 597,581,244.1 | 437,021,620.72 |
| 营业成本 | 125,899,235.73 | 57,588,093.59 | 217,642,521.57 | 161,290,949.46 |
| 税金及附加 | 8,070,593.4 | 3,702,201.48 | 14,329,993.19 | 10,863,071.94 |
| 销售费用 | 91,044,742.2 | 43,626,154.81 | 182,568,105.39 | 132,692,285.97 |
| 管理费用 | 54,911,117.02 | 26,418,166.68 | 127,852,670.78 | 88,823,175.31 |
| 研发费用 | 19,634,385.2 | 7,660,759.12 | 47,084,603.43 | 37,135,931.42 |
| 财务费用 | 2,805,678.7 | 1,425,192.5 | 8,103,349.74 | 6,216,206.62 |
| 其中:利息费用 | 2,629,797.03 | 1,317,196.42 | 11,091,000.93 | 8,799,172.07 |
| 其中:利息收入 | 102,547.13 | 51,924.6 | 3,043,495.33 | 2,960,701.09 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 20,035,272.46 | 9,494,809.94 | 43,238,688.36 | 30,981,776.88 |
| 资产处置收益 | 111,916.62 | 44,706.1 | 69,168,227.38 | 8,359,205.6 |
| 资产减值损失(新) | -6,910,539.37 | -2,218,785.13 | -26,596,192.71 | -2,496,163.19 |
| 信用减值损失(新) | -365,014.1 | -282,021.25 | 2,313,007.94 | 1,527,916.8 |
| 其他收益 | 2,768,166.43 | 1,528,687.8 | 16,294,325.01 | 8,310,319.95 |
| 四、营业利润 | 129,944,371.96 | 53,738,813.23 | 221,205,882.77 | 130,203,765.91 |
| 加:营业外收入 | 116,703.53 | 116,178.33 | 807,385.52 | 770,885.81 |
| 减:营业外支出 | 609,521.92 | 520,766.23 | 3,879,301.72 | 684,770.3 |
| 五、利润总额 | 129,451,553.57 | 53,334,225.33 | 218,133,966.57 | 130,289,881.42 |
| 减:所得税费用 | 15,514,593.83 | 6,465,512.37 | 17,347,706.39 | 13,280,729.6 |
| 六、净利润 | 113,936,959.74 | 46,868,712.96 | 200,786,260.18 | 117,009,151.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 113,936,959.74 | 46,868,712.96 | 200,786,260.18 | 117,009,151.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 112,423,618.95 | 45,793,170.61 | 200,700,773.72 | 117,073,573.87 |
| 少数股东损益 | 1,513,340.79 | 1,075,542.35 | 85,486.46 | -64,422.05 |
| 扣除非经常损益后的净利润 | 111,149,021.06 | 45,328,612.66 | 126,863,340.37 | 106,837,137.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.35 | 0.14 | 0.61 | 0.36 |
| (二)稀释每股收益 | 0.35 | 0.14 | 0.61 | 0.36 |
| 八、其他综合收益 | - | - | -229,502.16 | 29,129.17 |
| 归属于母公司股东的其他综合收益 | - | - | -206,551.94 | 26,216.25 |
| 九、综合收益总额 | 113,936,959.74 | 46,868,712.96 | 200,556,758.02 | 117,038,280.99 |
| 归属于母公司股东的综合收益总额 | 112,423,618.95 | 45,793,170.61 | 200,494,221.78 | 117,099,790.12 |
| 归属于少数股东的综合收益总额 | 1,513,340.79 | 1,075,542.35 | 62,536.24 | -61,509.13 |
| 公告日期 | 2025-08-27 | 2025-04-30 | 2025-04-30 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |